Spruce Biosciences, Inc.
SPRB
$0.0649
-$0.001-1.52%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.91M | 4.91M | 7.10M | 9.57M | 10.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.91M | 4.91M | 7.10M | 9.57M | 10.13M |
| Cost of Revenue | 46.94M | 46.42M | 36.06M | 43.00M | 48.04M |
| Gross Profit | -44.03M | -41.51M | -28.96M | -33.43M | -37.91M |
| SG&A Expenses | 13.98M | 14.64M | 14.28M | 14.06M | 13.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.92M | 61.06M | 50.34M | 57.06M | 61.55M |
| Operating Income | -58.01M | -56.15M | -43.24M | -47.49M | -51.43M |
| Income Before Tax | -55.45M | -53.04M | -39.43M | -43.11M | -46.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.45 | -53.04 | -39.43 | -43.11 | -46.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.45M | -53.04M | -39.43M | -43.11M | -46.75M |
| EBIT | -58.01M | -56.15M | -43.24M | -47.49M | -51.43M |
| EBITDA | -57.97M | -56.11M | -43.19M | -47.43M | -51.36M |
| EPS Basic | -1.32 | -1.28 | -0.96 | -1.05 | -1.15 |
| Normalized Basic EPS | -0.83 | -0.80 | -0.60 | -0.66 | -0.72 |
| EPS Diluted | -1.32 | -1.28 | -0.96 | -1.05 | -1.15 |
| Normalized Diluted EPS | -0.83 | -0.80 | -0.60 | -0.66 | -0.72 |
| Average Basic Shares Outstanding | 167.91M | 165.06M | 164.35M | 163.76M | 163.14M |
| Average Diluted Shares Outstanding | 167.91M | 165.06M | 164.35M | 163.76M | 163.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |